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Perspectives on reasons for non-adherence to
medication in persons with schizophrenia in
Ethiopia: a qualitative study of patients,
caregivers and health workers
Solomon Teferra1*, Charlotte Hanlon1,3, Teferra Beyero1, Lars Jacobsson2 and Teshome Shibre1
Abstract
Background: Levels of non-adherence to antipsychotic medication in persons with schizophrenia in rural African
settings have been shown to be comparable to those found in high-income countries. Improved understanding of
the underlying reasons will help to inform intervention strategies relevant to the context.
Methods: A qualitative study was conducted among persons with schizophrenia (n = 24), their caregivers (n = 19),
research field workers (n = 7) and health workers (n = 1) involved in the ongoing population-based cohort study,
‘The Butajira Study on Course and Outcome of Schizophrenia and Bipolar Disorder’, based in rural Ethiopia. Six focus
group discussions and 9 in-depth interviews were conducted to elicit perspectives on non-adherence to
antipsychotic medication. Thematic analysis was used to identify prominent perspectives.
Results: Predominant reasons for non-adherence specific to a low-income country setting included inadequate
availability of food to counter appetite stimulation and the perceived strength of antipsychotic medications. The
vital role of the family or other social support in the absence of a statutory social safety net was emphasised.
Expectations of cure, rather than need for continuing care, were reported to contribute to non-adherence in the
longer-term.
Many of the factors associated with non-adherence in high-income countries were also considered important in
Ethiopia, including lack of insight, failure to improve with treatment, medication side effects, substance abuse,
stigma and dissatisfaction with the attitude of the care provider.
Conclusion: This study identifies additional barriers to medication adherence faced by persons with schizophrenia
in Ethiopia compared to those in high-income countries. In this era of scaling up of mental health care, greater
attention to provision of social and financial assistance will potentially improve adherence and thereby enable
patients to benefit more fully from medication.
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Background
The discovery of antipsychotic medications has improved
outcomes in persons with schizophrenia through control
of symptoms [1,2]. Several reports, including from the
population-based cohort of persons with schizophrenia
in Ethiopia, have shown that adherence to medication
is associated with better clinical outcome and lower
mortality [3-5].
In practice, the biggest challenge to the effectiveness
of antipsychotic medications has been ensuring treat-
ment adherence, defined as ‘the extent to which a per-
son’s behaviour coincides with the medical advice given’
[6]. Measures of adherence vary greatly from study to
study including varying percentage times medication
was taken, gap in time when no medication was available
and pharmacy based measures, the ‘gold standard’ being
Medication Event Monitoring (MEM), with a recorder
on pill bottle caps measuring time and date when
opened [7]. A comprehensive review of the literature
had shown at least half of patients prescribed with anti-
psychotic medications failed to take them [8]. Similar
levels of non-adherence were found in our Ethiopian
sample [3,4].
Non-adherence to antipsychotic medication is associ-
ated with increased risk of relapse, more frequent
hospitalization and poorer quality of life [9-11].
Several studies from high-income countries exploring
reasons for non-adherence to antipsychotic medication,
including some qualitative studies, reported the most
common reasons for non-adherence to be lack of in-
sight, low therapeutic alliance [12,13], the presence of
positive symptoms, being male, substance abuse, un-
employment and low social functioning [6]. Side effects
of antipsychotic medications and their subjective tolera-
bility by patients were also reported as reasons affecting
adherence [14,15].
There is a dearth of evidence on non-adherence from
low and middle income (LAMI) countries. In a qualita-
tive study from South Africa, persons with mental illness
reported that long queues when attending for out-
patient appointments, which involved a risk of being
physically attacked, was an important reason for their
non-adherence [16].
Ethiopia has just launched the first National Mental
Health Strategy, committing to scale-up of mental health
care across the country [17]. In addition, Ethiopia is a
pilot site for the WHO’s mental health Gap Action
Programme (mhGAP) [18], implemented in collabo-
ration with the Ministry of Health. Improving acce-
ssibility of medication is a critical first step in this
setting where fewer than 10% of persons with schizo-
phrenia ever received effective treatment [19], but this
needs to be coupled with interventions to maximize
adherence.
The cohort of patients with schizophrenia in Butajira
has been under follow up for over a decade, and from
this cohort study, important new evidence emerged
regarding the epidemiology of schizophrenia and clinical
course and outcome including mortality in a rural
African setting. Antipsychotic medications were found
to have significant impact in improving clinical course
and outcome as well as reducing premature mortality.
Unfortunately, adherence to antipsychotic medications
was found to be low; this is the reason that prompted us
to undertake the current study.
In this qualitative study, we explored the reasons for
low adherence to medication in a rural Ethiopian setting
from the perspectives of people with schizophrenia, their
caregivers, research field workers and health workers
with a view to informing interventions to mitigate the
problem.
Methods
Setting, study design and participants
The study was conducted in Butajira town and the sur-
rounding rural villages, located 135 km south of Addis
Ababa, the capital of Ethiopia. The main livelihoods are
trade in urban areas and farming in rural areas. The
psychoactive stimulant plant, that, is also widely grown
as a cash crop. The area is small, but has diverse climatic
and geographical features.
This qualitative study was nested within the cohort
study “Course and Outcome of Schizophrenia and Bipo-
lar Disorder in Butajira”. The original study involved as-
certainment of persons with schizophrenia or bipolar
disorder from a community survey of more than 68,000
people using lay interviewers, key informants and
clinician-administered diagnostic interviews [19]. Three
hundred and twenty one persons with schizophrenia
were identified at baseline and have been followed up
for over a decade [19]. This project provided a unique
opportunity for the population in Butajira by making
modern mental health care accessible via a psychiatric
nurse-led out-patient unit located in Butajira general
hospital. As a benefit of participating in the project,
patients were provided free consultation and medication
on a regular basis. Prior to the project, people with
severe mental disorders living in the Butajira area would
have needed to travel to the only psychiatric hospital in
the country, located in the capital city, Addis Ababa, in
order to receive care. Indeed, for centuries, traditional
and religious healers were the major sources of care for
people with mental illnesses in Butajira as is the case in
rural Ethiopia in general. Details of how mental disor-
ders are seen by the community and where help was
sought in Butajira can be found in a report by Alem
et al. [20]. The training of large numbers of specialized
mental health nurses has resulted in an expansion of
Teferra et al. BMC Psychiatry 2013, 13:168 Page 2 of 9
http://www.biomedcentral.com/1471-244X/13/168
basic mental health services across the country [21] Fur-
ther scale-up of mental health care is underway by inte-
grating mental health services into primary care and
general health care facilities. Outside of the main urban
centers, only a limited choice of psychotropic medica-
tions is available: first generation antipsychotics (mostly
chlorpromazine, and sometimes haloperidol, trifluopera-
zine and fluphenazine decanoate depot) and older anti-
depressants (amitriptyline). Medications to alleviate
movement side effects of first generation antipsychotic
medications (e.g. anticholinergic medication) are rarely
available. Psychiatric care is mainly pharmacologic;
hence, for the majority of patients with severe mental
illnesses in Ethiopia, there is no long-term psychosocial
rehabilitation service.
Six focus group discussions (FGDs), composed of 6 to
8 participants, and nine in-depth interviews (IDIs) were
conducted involving persons with schizophrenia, their
caregivers and health care and research field workers. Of
these, three FGDs and four IDIs involved patients, two
FGD and four IDIs for caregivers, and one FGD for
mental health research field workers who provide com-
munity outreach to the patients. One IDI was carried
out with a psychiatric nurse in the Butajira hospital psy-
chiatric clinic. We chose to conduct both FGDs and IDIs
because these different methods of data collection can
yield complementary information. In FGDs, it is possible
to see how diverse views are held in relation to one an-
other and how the topic is discussed in front of others.
On the other hand, a potential advantage of IDIs is that
it may be easier to explore potentially sensitive topics
that participants might not feel comfortable to discuss in
groups, for example relating to stigma or sexual side
effects of medications. As per recommendations for the
conduct of FGDs [22], participants within a group were
homogenous as far as possible in order to facilitate a
free and open discussion and ‘capitalize on shared expe-
riences’ [22].
As previous reports have found differing views re-
garding factors affecting adherence among patients,
caregivers and health professionals [14,23], we included
participants representing these three perspectives. Any
future intervention to try to improve adherence levels
would need to take into account caregiver perspectives
given the active decision-making role that families play
in the mental health care of an affected family member.
Project field workers identified potential respondents
and invited them to participate. Purposive sampling
was employed to identify patients who had a history of
non-adherence to antipsychotic medications, and later
in the process, we also interviewed patients with appa-
rently high levels of adherence in order to understand
their perspective and incorporate into the emerging
themes.
Non-adherence was defined as failing to take pre-
scribed antipsychotic medication in the previous month
as reported by patients and family members. Health pro-
fessionals also considered those patients missing their
clinic appointments as non-adherent, as the clinic was
the only way for patients to access medications.
A topic guide was developed by the authors and used
to guide exploration of the perceived factors affecting
adherence. As data collection progressed, CH met with
TB on regular basis to discuss the transcripts and allow
iterative development of the topic guide to explore
emerging themes in greater depth. The topic guide in-
cluded questions related to explanatory models of illness
(including symptoms, causes, course and appropriate in-
terventions), open questions about the experience of be-
ing treated with psychotropic medications and perceived
reasons for non-adherence; followed by probing with
direct questions about the impact of substance use and
the nature of the interaction with mental health workers
upon adherence All IDIs and FGDs were conducted by
TB, a physician who was head of the research project
site and involved in treating patients as well as providing
consultation to the psychiatric nurses. The transcripts
indicated that most participants appeared comfortable
discussing reasons for non-adherence. The IDIs and
FGDs took place close to where patients lived and lasted
from 30 to 90 minutes.
Data analysis
The IDIs and FGDs were tape recorded. Hand written
notes were also taken when deemed necessary. The au-
diotapes were transcribed into Amharic, Ethiopia’s offi-
cial language, and then translated into English by TB.
TB, ST and CH read through all of the transcripts.
Thematic analysis, the most widely used method in
qualitative studies [24], was used to identify prominent
perspectives on non-adherence. The theoretical position
we took was that of ‘essentialist or realist method, which
reports experiences, meanings and the reality of partici-
pants’ [24]. Coding was done manually, close-to-the-text,
and was thus inductive [24], paying attention to key
words that described an idea followed by categorization
into themes. We coded patients’, caregivers’, field
workers’ and health care worker’s responses separately
and explored how each group differed by comparing
across the groups of participants. A joint meeting was
held to discuss the codes and identified themes.
According to Braun and Clarke, ‘a theme captures some-
thing important about the data in relation to the re-
search question, and represents some level of patterned
response or meaning within the data set.’ [24]. There
were no major differences among the authors with
regards to the salience of the identified themes.
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Ethical considerations
The study had ethical approval from the Science and
Technology Agency of Ethiopia and Faculty of Medicine
Research and Publication Committee, Addis Ababa
University. Participants were informed about the pur-
pose of the study, their right to refuse to participate
without any adverse impact on the care they received, as
well as measures to ensure confidentiality. After this
explanation, they provided verbal consent.
Results
Participants identified a number of factors that were
considered to affect adherence to antipsychotic medi-
cations in persons with schizophrenia. There was a
substantial overlap in the responses from the four
groups of participants and therefore, for the most part,
their perspectives are presented together. Issues that
were emphasized by a particular group are presented
separately.
Poverty
The most frequent reason for non-adherence anti-
psychotic medications mentioned by participants was
lack of adequate and proper food. Antipsychotic medica-
tions were reported to be ‘strong’ which require ‘good’
food in order to counterbalance their side effects. If
taken on an empty stomach, both patient and caregiver
participants reported that the medications would cause
harm to the body. As a consequence, patients were liable
to stop their medications whenever there was a shortage
of food. Lack of food was also important from another
perspective. Participants reported that the medications
led to increased appetite. This was reported to have two
negative effects: either a burden on the family because of
increased food consumption by the patient or, in the
event of limited food availability, the experience of
hunger. Many participants spoke of being forced to
discontinue their medications because they found the
increased hunger difficult to tolerate. A patient partici-
pating in one of the groups described it as follows:
“If we had good foods like vitamins, we could have
withstood the effect of the drugs. The drugs make you
weak especially when they are not taken with proper
food. Our minds get clearer, but our bodies are getting
weaker.”
The health worker (psychiatry nurse) also agreed with
this by stating the reports he heard that medications
made patients hungry, and they had to stop it whenever
they couldn’t get enough food.
“Yes, there are people who have said they couldn’t to-
lerate the hunger and stopped taking it [the medication].
I have also met families who made them stop taking the
drug because they can’t afford to feed them when the
patients take the drug, as it makes them eat a lot. There
are families who have told me that they had no resources
to feed them. This reason is often cited as a factor for
stopping treatment.”
Lack of support from family
Patients mentioned lack of support from their family as
one of the most important reasons for discontinuing
treatment and follow up. Indeed, respondents com-
mented that adherence was impossible without the ac-
tive involvement of the family. Various reasons were
given for the decrease in family support observed in
some cases, including competing work demands for
family members. A participant in a patient’s group said:
“My family used to take care of me when I was sick,
but now when I ask them to accompany me here [to the
hospital] for the follow up, none of them are coopera-
tive. I have to beg them and plead with them. Even my
wife says she has a lot of work to do and can’t come; she
doesn’t realize that if I get sick she is also going to
suffer.”
Acute illness perspective and stigma
Participants reported that the need for long-term treat-
ment even in the absence of symptoms was alien,
leading patients to discontinue their medication prema-
turely, as illustrated below by a participant in field
worker’s group:
“When I visit them, I ask them why they have stopped
taking the medication, and many of them tell me that
they stopped taking the medication because they felt bet-
ter. When they get better and start to work and lead a
normal social life, they don’t see the need to continue
taking the medication.”
Stigma was mentioned to be a powerful barrier to ad-
herence, especially among those who had improved and
were now functioning well. It was reported that this
group did not want to be considered mentally ill and did
not want to be seen having any contact with mental
health professionals. One of the field workers said:
“I have also met people who do not want [other]
people to know that they are mentally ill. One, for
example, told us not to talk to him in public and has
stopped the medication just because he didn’t want
others to know that he is mentally ill. There is also an-
other who wants to be given the treatment as soon as he
arrives and goes away before meeting anybody. A patient
by the name… has told me to just greet him when I
meet him in the village, but not talk to him for any
length of time or ask him whether he feels well or not.”
Related to the health care provider
Although not consistent across participants, another
recurring reason for non-adherence that was especially
emphasized by caregivers, field workers and the health
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worker related to the mental health service. The atti-
tudes and behaviour of health workers were sometimes
reported to be off-putting. Some respondents reported
feeling ashamed if they missed one appointment and
that this would deter them from attending again because
of the risk of a negative response from the health
worker. The long waiting times and inflexibility of the
appointment system also deterred people from continu-
ing with treatment.
Clinical factors
Side effect of medications
The other most frequently mentioned reason was side-
effects of medications. Patients mentioned several
distressing side-effects such as ‘paralysis of the body’,
twisting of the neck, drooling of saliva, weakness, and
daytime sleepiness which interfered with their func-
tioning. The critical impact of appetite stimulation on
adherence has already been described in relation to
the first theme.
Concurrent alcohol and drug use
Alcohol drinking and khat, an amphetamine-like sti-
mulant, chewing were reported to be important factors
adversely affecting adherence. Caregivers, field workers
and health workers especially emphasized the role of
alcohol and khat in affecting adherence. One caregiver
said ‘He doesn’t take the medicine; he says it prevents
him from chewing khat.’ Sometimes the caregivers
themselves would not give patients the medication when
they drank alcohol saying alcohol did not agree with the
medication. A caregiver reported:
“He says, ‘I have taken alcohol, and therefore, I will not
take the tablets.’ He says, ‘It doesn’t suit me, it makes me
uncomfortable. He even says ‘I have now finished the
tablets, so give me some araki [strong locally brewed
liquor]’.”
Lack of insight
Patients’ lack of awareness of having a mental illness
was another barrier that was observed by family mem-
bers for not adhering to medication. Family members
were involved in reminding patients about appoint-
ments, bringing patients to the hospital and ensuring
that they took the medications. The following quote il-
lustrates the challenges faced by the caregivers.
“We usually urge him [the patient] to go to the hos-
pital for the follow-up for his treatment. We would tell
him he would be given money there. He would some-
times become angry with us. They [the health workers]
tell us to give him the tablets daily. At first, he agreed to
take the tablets himself on his own. He took it from me
and put it in his pocket. He sometimes would take it
and sometimes miss it, and finish it somehow. But, later
on, he would just disappear when his appointment date
comes.”
Similarly, according to experiences reported the cli-
nician, lack of insight was among the barriers affecting
patients’ willingness to come to the hospital to collect
their medications or get their monthly injections and the
role of the family as ‘substitute insight’ as illustrated
below:
“Because patients have no insight, their insights are
their families. Therefore, there are a lot of people who
stop taking their medications because of lack of insight.”
Discussion
In this qualitative study from rural Ethiopia we explored
the reasons for non-adherence to antipsychotic medica-
tions in persons diagnosed with schizophrenia, from the
perspectives of patients, their families, health pro-
fessionals and research field workers. Several of the
reported reasons for non-adherence were in keeping
with previous findings from high-income countries
[6,8,16], illustrating commonalities across settings. How-
ever, the particular contribution of this study was the
finding that those factors considered most important to
medication adherence were peculiar to this low-income
country setting.
Economic factors such as lack of access to adequate
nutrition emerged as the most salient factor for non-
adherence from the perspective of the respondents.
Chronic food insufficiency is still common in the study
site [25] despite recent positive developments in the
country, and patients with severe mental illnesses were
reported to have more chronic energy deficiency com-
pared with their healthy counterparts [26]. In fact, a
5-year mortality report from the same cohort of patients
with schizophrenia showed severe malnutrition as the
second most common cause of death, accounting for
13.2% of the deaths [4]. In a situation where there is
food shortage at the household level, healthy members
of the family get the priority.
The inter-relationships between food insufficiency and
non-adherence to antipsychotic medication appear to be
multi-faceted. Antipsychotic medications are known to
increase appetite and craving for food which is generally
believed to be mainly through stimulation of the hista-
minergic neurotransmitter system [27]. Appetite stimu-
lation by the medication would lead to feeling of hunger
(subjectively distressing) or increased food consumption
(increased burden on family). While there are some
studies from western countries, where there is abun-
dance of high fat and high calorie foods, suggesting
increased appetite and the consequent weight gain ad-
versely affecting adherence to antipsychotic medications
[28], there is paucity of data from low income countries
where food is scarce. But, a review of the HIV literature
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from sub-Saharan African countries indicated lack of
food or hunger being an important factor affecting
adherence. Patients reported increased appetite caused
by the medications, and inability to get adequate food
forced them to stop the medications [29,30]. This same
experience was reported by our patients as well as their
caregivers.
A previous qualitative exploration of purposively
selected patients from the Butajira course and outcome
study found that one of the justifications patients
gave for ongoing chewing of the leaves of khat, an
amphetamine-like stimulant which has anorexigenic
properties, was as a means to curb their appetite. Family
caregivers who couldn’t provide food would allow pa-
tients to chew khat despite being aware of its negative
impact on the patient’s illness such as worsening of
symptoms [31]. However, another factor linked inad-
equate food availability with non-adherence: perceiving
the medication to be ‘strong’, requiring the person to
take adequate food in order to be able to tolerate it,
emerged as a strong factor affecting adherence. The
apparent fatigue which could potentially be caused by
the typical, low potency antipsychotic medications
(e.g. chlorpromazine and thioridazine) that the patients
were taking was perceived to be caused by the lack of a
balanced diet [32].
Another important factor reported to affect medica-
tion adherence was the role of the family in the care of
patients. In the absence of community-based mental
health care, patients relied on family to access care.
Patients may be too unwell, lack insight or be disabled
by negative and cognitive symptoms of schizophrenia, to
be able to remember their appointment dates and attend
clinics on their own, particularly as health facilities are
usually some distance from the patient’s place of resi-
dence. As well as enabling the patient to access care,
family members also play an important role in ensuring
that their affected relative takes their medication,
through reminders and encouragement. A recent ran-
domized controlled study carried out in Peshawar,
Pakistan, found that adherence significantly improved
whenever patients were supervised by relatives, an ap-
proach which the authors called STOPS, Supervised
Treatment in Out-Patient for Schizophrenia [33]. The
actions of family members to promote adherence may
go beyond mere encouragement. In this study, some
family members went so far as to mix the medication
with drinks (tea, milk) covertly, while others employed
various coercive techniques to make the patients under
their care take the medication. Such covert administra-
tion of treatment and coercion is commonly practiced
on patients living in LAMI countries [34]. It has been
argued that, for severely unwell persons who lack the
capacity to make decisions about their treatment, and in
the absence of adequate community-based services,
such actions may serve to promote, rather than under-
mine, a patient’s autonomy through restoring their
health [35]. However, patients can be abused in the
process, in addition to issues relating to autonomy and
consent [36].
Exclusive reliance upon family support is also prob-
lematic when such support is not consistently present,
as was reported to be the case by participants in this
study. Caregiver burden, both economic and emotional,
may contribute to the waning support over time, al-
though a previous report from this study showed that
accessing effective treatment was one of the most im-
portant factors in alleviating burden [37]. Without the
support of families, many persons with schizophrenia
and other severe mental disorders in this setting become
vagrants or destitute, contributing to their greatly re-
duced life expectancy [4].
The other important factor reported to affect adher-
ence was lack of knowledge about the nature of the ill-
ness, the medications and the expected outcome from
the treatment. Considering apparent absence of symp-
toms as cure led to discontinuation of treatment. Or on
the contrary, they expected too much from the treat-
ment, and when ‘cure’ didn’t happen, they abandoned
the medications and sought help from alternative health
care such as holy water treatment, ‘tsebel’, or consulted
traditional/ indigenous healers. In a rural Ethiopian set-
ting where the burden of acute, curable infectious dis-
ease is high, patients and caregivers may find it difficult
to shift to a chronic disease model of care and accept
the need to continue taking medication [38].
Stigma was another factor reported to affect adher-
ence. Having a severe mental illness such as schizophre-
nia is highly stigmatizing in the area, with low prospects
for work or marriage [20]. It is not only the patients, but
also their relatives who are stigmatized [39]. This issue
was particularly relevant for patients who were no longer
suffering from any symptoms. After showing some im-
provement, patients were liable to decline the offer of
continued care and stop their medication. They were
not even willing to talk with the mental health field
workers or psychiatric nurses whenever they visited
them in their villages.
In this study, one of the reported factors affecting ad-
herence to antipsychotic medications was lack of insight.
As reported time and again by family members, lack of
insight led to refusal to take medications. Lack of insight
is one of the hallmarks of psychosis [40]. There are sev-
eral explanations for lack of insight in schizophrenia in-
cluding cognitive deficits, denial of symptoms or a lack
of adaptive personal narrative understanding of illness
[41]. Although we didn’t specifically look into reasons
for lack of insight in the study participants, given the
Teferra et al. BMC Psychiatry 2013, 13:168 Page 6 of 9
http://www.biomedcentral.com/1471-244X/13/168
diverse nature of their clinical status, the aforemen-
tioned reasons could apply to them as well. There is a
complex relationship between insight and medication
adherence. Several studies have shown that it is probably
one of the most important factors affecting adherence
and thereby resulting in poorer outcome [12,42-44]. On
the contrary, there are reports which showed that pa-
tients might continue to take medication, although they
do not believe they have mental illness, because of relief
of symptoms from taking medications [24,45].
Medication side effects were frequently cited as an im-
portant factor leading to non-adherence in this setting.
The only antipsychotic medications available to the
patients in the study were a very limited selection of first
generation antipsychotic medications (FGAs). These
FGAs have the potential to cause distressing side effects
in a context where medications to counter side effects is
erratically available. Several studies on medication ad-
herence identify side effects as a very important factor
affecting adherence [14,15,46]. Unfortunately, the hope
that second generation medications would have greater
tolerability and, therefore, improved adherence has not
been borne out in practice [47,48].
The behavior of some of the health care providers was
also mentioned as a factor affecting adherence. Several
studies have shown that the therapeutic alliance with pa-
tients plays an important role in adherence to prescribed
treatments [49-51].
Substance abuse was also reported to be a common
reason for non-adherence. Patients who chewed khat
and drank alcohol had a reportedly low level of adhe-
rence to antipsychotic medications. In keeping with
these findings, a previous qualitative study nested in the
Butajira cohort study also reported that patients did not
like the idea of taking khat and medication together be-
cause of fears that harm would result from combining
two powerful chemicals [31]. Co-morbid substance
abuse is known to adversely affect adherence to treat-
ment in patients with schizophrenia in high-income
countries, and a similar picture appears to pertain in a
rural African setting [8,13].
The main limitation in this study is the broad defi-
nition of non-adherence i.e. subjective report by patients
of not taking their medication, family members’ report
or a report by health professional based on a missed
clinic appointment. Not all participants, patients and
families mentioned non-adherence as a problem for
them personally, which could be related to social desi-
rability bias or fear of retribution because the inter-
viewer was a doctor working in the psychiatry clinic.
Without an objective measure of adherence we couldn't
evaluate the impact of social desirability. However, we
did know their adherence history as documented in the
monthly follow-ups by the Butajira study nurses. So, we
had contemporaneous, independent indicators of adher-
ence and were not relying solely on self-report.
Conclusion
In this qualitative study from rural Ethiopia, we identi-
fied those factors considered to be most important for
adherence as reported by patients, families, research
field workers and health workers. Based on these find-
ings, the following recommendations can be made: inter-
ventions that address food insecurity have the potential
to substantially improve adherence by (1) reducing the
suffering associated with medication-induced appetite
stimulation (2) alleviating strongly held concerns that
medication is too potent to be taken without adequate
nutrition, and (3) relieving the economic burden on fam-
ilies thus enabling them to provide the ongoing support.
Such an approach is supported by a recent WHO report
which identified persons with severe mental disorders as
a vulnerable group to be prioritized for aid and deve-
lopment activities in low-income countries [52]. Families
of persons with schizophrenia should, therefore, be
targeted by the existing ‘Productive Safety Net Pro-
gramme’ present in chronically food-insecure areas of
Ethiopia. Non-governmental organizations can also play
a role in supporting the basic needs of patients, for
example, for livelihoods and adequate nutrition. In this
respect much can be learned from the strategies used to
expand the uptake of antiretroviral therapy in persons
living with HIV/AIDS in Ethiopia, where similar factors
affected adherence. According to the 2012 country pro-
gress report, 103,659 poor HIV positive Ethiopians
received food support in addition to medication by the
end of June 2011 [53]. Other measures include integra-
tion of mental health in primary care to ensure access
close to where patients live, equip workers with commu-
nication skills that will optimize development of a good
therapeutic alliance, ongoing psychoeducation to pa-
tients and their families, improve management of medi-
cation side effects and concurrent misuse of substances.
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